摘要目的 观察吲哚胺2,3双加氧酶(IDO)在肝细胞肝癌(HCC)中的表达,分析其表达与临床病理参数的关系.方法 采用逆转录-聚合酶链反应(RT-PCR)、荧光定量PCR、免疫组化、免疫荧光研究IDO在HCC中的表达.结果 IDO mRNA在癌组织中的表达比相应的非癌组织明显增高(2-△△CT=1.71,P=O.001),△CT值在癌组织中为6.40±2.21,非癌组织中7.17±1.90,正常肝脏组织中7.61±0.93.IDO蛋白主要在癌边缘及癌组织的胞质中表达,而在非癌及肝脏良性病变的正常肝脏组织内则不表达.IDO表达的强弱与术后复发及生存时间、是否发生转移、TNM分期有关(P＜0.05)；与肝硬化、AFP、病理分化、巴塞罗那分期、性别、年龄、乙肝表面抗原、肿瘤大小及数目无关(P＞0.05).结论 IDO的高表达可能会影响HCC患者的愈后.

abstractsObjective To explore the expressions of indoleamine 2,3-dioxygenase (IDO) in hepatocellular carcinoma and analyze its relationship with clinicopathological parameters.Methods Quantitative real-time polymerase chain reaction (PCR),fluorogenic quantitative PCR,immunohistochemical and immunofluorescence were used to detect the expression of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.Results The IDO mRNA expression in cancerous tissues increased markedly than that in the corresponding non-cancerous tissues (2-△△CT =1.71,P =0.001).The immunohistochemical and immunofluorescence results showed that IDO protein was expressed in cytoplasm of hepatocellular carcinoma and tumor-surrounding tissues.But there was no expression in normal liver tissues from benign hepatic lesions and corresponding non-cancerous tissues.An over-expression of IDO protein was detected in 43 patients(48.3％),a low expression in 25 (28.1％) and no expression in 21 (23.6％).Relationship between IDO expression and clinicopathological parameters:an over-expression of IDO in HCC was associated with recurrence,survival time,metastasis and TNM stage (P ＜ 0.05),but not associated with patient's cirrhosis,AFP level,histological differentiation type,Barcelona clinic liver cancer stage,gender,age,HbsAg positivity,number of tumors and tumor size (P ＞ 0.05).Conclusion An overexpression of IDO in HCC patients may affect patient prognosis.